Acute Promyelocytic Leukemia

CD34 Cells May Be Linked To Poor Prognosis

Published in Blood Weekly, June 14th, 2001

by Michael Greer, senior medical writer - Acute promyelocytic leukemia (APL) patients carrying CD34⁺ malignant cells may have less positive prognoses than other APL patients, researchers say.

"Current [APL] therapy includes chemotherapy used in combination with all-trans-retinoic acid (ATRA)," explained R. Foley and colleagues at Henderson General Hospital in Ontario. "Although the differentiating effects of ATRA on promyelocytes have been well established, in vitro studies have shown that less-differentiated APL blasts (CD34⁺) demonstrate a variable responsiveness to ATRA."

Foley and coworkers found that APL patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry